48,830
edits
Difference between revisions of "Lung tumours"
Jump to navigation
Jump to search
→Malignant mesothelioma: +IHC
m (→Molecular) |
(→Malignant mesothelioma: +IHC) |
||
| Line 296: | Line 296: | ||
===IHC=== | ===IHC=== | ||
====Mesothelioma versus mesothelial hyperplasia==== | |||
Features:<ref name=pmid20209622>{{Cite journal | last1 = Hasteh | first1 = F. | last2 = Lin | first2 = GY. | last3 = Weidner | first3 = N. | last4 = Michael | first4 = CW. | title = The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. | journal = Cancer Cytopathol | volume = 118 | issue = 2 | pages = 90-6 | month = Apr | year = 2010 | doi = 10.1002/cncy.20071 | PMID = 20209622 }}</ref> | |||
*EMA +ve ~100% (vs. ~10%). | |||
*Desmin -ve ~5% (vs. ~85%). | |||
*GLUT1 +ve ~50% (vs. ~10%) | |||
*p53 +ve ~50% (vs. ~2%). | |||
====Mesothelioma versus adenocarcinoma==== | |||
*Several panel exists - ''no agreed upon best panel''.<ref name=pmid18318582>{{cite journal |author=Marchevsky AM |title=Application of immunohistochemistry to the diagnosis of malignant mesothelioma |journal=Arch. Pathol. Lab. Med. |volume=132 |issue=3 |pages=397-401 |year=2008 |month=March |pmid=18318582 |doi= |url=http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=132&page=397}}</ref> | *Several panel exists - ''no agreed upon best panel''.<ref name=pmid18318582>{{cite journal |author=Marchevsky AM |title=Application of immunohistochemistry to the diagnosis of malignant mesothelioma |journal=Arch. Pathol. Lab. Med. |volume=132 |issue=3 |pages=397-401 |year=2008 |month=March |pmid=18318582 |doi= |url=http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=132&page=397}}</ref> | ||
**Usually two carcinoma markers + two mesothelial markers. | **Usually two carcinoma markers + two mesothelial markers. | ||